Harrow, Inc. has filed a Current Report on Form 8-K with the Securities and Exchange Commission disclosing a corporate presentation intended for the Jefferies Global Healthcare Conference held in London in November 2026. The filing details the company’s financial performance and strategic outlook for the remainder of the year and into 2027.

According to the presentation, Harrow reported record third-quarter revenue of $99.3 million, representing a 41% increase compared to the prior quarter. The company projects full-year 2026 revenue between $350 million and $365 million. For the fourth quarter, management anticipates revenue of approximately $135.8 million and adjusted EBITDA of $33 million or more.

The filing highlights three core brands driving growth: VEVYE, IHEEZO, and TRIESENCE. VEVYE, a treatment for dry eye disease, generated $39.7 million in Q3 2026, a 75% increase year-over-year. IHEEZO, an ocular anesthetic, saw unit demand rise 21% compared to the prior year, while TRIESENCE, a preservative-free injectable steroid, achieved record revenue of $10.7 million.

Management emphasized operating leverage, noting that the company expanded its sales team to four teams with a shared cost base. This structure allowed revenue to grow 41% sequentially while maintaining flat selling, general, and administrative expenses. The company reported a 78% incremental adjusted EBITDA conversion rate in the third quarter.

Looking ahead, Harrow outlined a pipeline of new product launches planned through 2030. The company acquired a dry eye nasal spray in October, which is expected to generate over $30 million in revenue in 2027. Additionally, the company launched a biosimilar for Lucentis in July 2026 and plans to launch a biosimilar for Eylea in 2027. The company also provided a timeline for G-MELT, a sedation tablet, indicating an NDA submission by year-end 2026 and a potential launch in early 2028.